Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy

PLoS One. 2014 Oct 16;9(10):e110531. doi: 10.1371/journal.pone.0110531. eCollection 2014.

Abstract

Purpose: To investigate the vitreous and plasma levels of vascular endothelial growth factor (VEGF) in patients with proliferative diabetic retinopathy (PDR) and to determine whether they predict a disease prognosis after primary vitrectomy.

Methods: Fifty patients (50 eyes) with PDR who underwent pars plana vitrectomy (PPV) and 56 healthy controls (56 eyes) were enrolled in this retrospective study. Clinical data were collected and analyzed. Vitreous and plasma VEGF concentrations were measured using enzyme-linked immunosorbent assays. VEGF levels and clinical data were compared and analyzed to see if they provide a prognosis of PDR progression after primary vitrectomy at more than 6 months follow-up. Correlation of VEGF concentrations between vitreous fluid and plasma was analyzed.

Results: The average BCVA was significantly improved after surgery (P<0.001). Vitreous and plasma VEGF levels were significantly elevated in PDR patients than those in healthy controls (P vitreous<0.001; P plasma<0.001). Both vitreous and plasma VEGF levels were significantly higher in PDR progression group than in stable group (P vitreous < 0.001; P plasma = 0.004). Multivariate logistic regression analyses showed that the increased vitreous VEGF level was associated with the progression of PDR after primary PPV (OR = 1.539; P = 0.036). Vitreous VEGF level was positively associated with plasma VEGF level in PDR patients (P<0.001).

Conclusion: The increased VEGF level in vitreous fluid may be identified as a significant predictive factor for the outcome of vitrectomy in patients with PDR.

MeSH terms

  • Adult
  • Aged
  • Diabetic Retinopathy / blood*
  • Diabetic Retinopathy / pathology
  • Disease Progression
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prognosis*
  • Vascular Endothelial Growth Factor A / blood*
  • Vitrectomy / adverse effects*
  • Vitreous Body / metabolism

Substances

  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A

Grants and funding

These authors have no support or funding to report.